Rashid, Waqar;
Ciccarelli, Olga;
Leary, Siobhan M;
Arun, Tarunya;
Doshi, Anisha;
Evangelou, Nikos;
Ford, Helen L;
... Association Of British Neurologists Multiple Sclerosis and Neuro; + view all
(2024)
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.
Practical Neurology
10.1136/pn-2024-004228.
(In press).
Preview |
Text
Ciccarelli_DMT_Guidance_final_revisions_030924.pdf Download (300kB) | Preview |
Abstract
The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
